Patients with LR hypertension constitute 30% of the essential hypertensive population, including a proportion of patients often resistant to conventional medications. 5 This stimulating trial by Hood et al 1 2 demonstrates that spironolactone is a valid option for the treatment of LR hypertensives, combining high efficacy with neutral metabolic effects.
Letter regarding article by Hood et al, "The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio"
MULATERO, Paolo;VEGLIO, Franco
2008-01-01
Abstract
Patients with LR hypertension constitute 30% of the essential hypertensive population, including a proportion of patients often resistant to conventional medications. 5 This stimulating trial by Hood et al 1 2 demonstrates that spironolactone is a valid option for the treatment of LR hypertensives, combining high efficacy with neutral metabolic effects.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Circulation-2008-Mulatero-e151.pdf
Accesso riservato
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
297 kB
Formato
Adobe PDF
|
297 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
